Log in

Relevant bibliographies by topics / Fatty liver disease / Dissertations / Theses

To see the other types of publications on this topic, follow the link: Fatty liver disease.

Dissertations / Theses on the topic 'Fatty liver disease'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 dissertations / theses for your research on the topic 'Fatty liver disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Bayard, Max, Jim Holt, and Eileen Boroughs. "Nonalcoholic Fatty Liver Disease." Digital Commons @ East Tennessee State University, 2006. https://dc.etsu.edu/etsu-works/6487.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bayard, Max, and Jim Holt. "Non-Alcoholic Fatty Liver Disease." Digital Commons @ East Tennessee State University, 2007. https://dc.etsu.edu/etsu-works/6495.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Levene, Adam Phillip. "Steatosis in non alcoholic fatty liver disease." Thesis, Imperial College London, 2012. http://hdl.handle.net/10044/1/9691.

Full text

Abstract:

Non-alcoholic fatty liver disease is the commonest cause of chronic liver disease in developed countries. The accurate assessment of steatosis is central to the diagnosis of non-alcoholic fatty liver disease. I compared the assessment of steatosis by histology, biochemical triglyceride assays, digital image analysis, with and without Oil Red-O staining, in mouse livers and human liver biopsies. In each case Oil Red-O digital image analysis was the most reliable technique for quantitating steatosis. I then investigated a potential, non-invasive technique for distinguishing steatosis from steato

APA, Harvard, Vancouver, ISO, and other styles

4

De, Alwis Nimantha M. W. "Mitochondrial dysfunction in non alcoholic fatty liver disease." Thesis, University of Newcastle Upon Tyne, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.493235.

Full text

Abstract:

Non Alcoholic fatty Liver disease (NAFLD) is the commonest chronic liver disease worldwide and is a spectrum which includes simple fatty liver (simple steatosis), non-alcoholic steatohepatitis (NASH) and cirrhosis. Simple steatosis is a benign condition but NASH may progress to liver fibrosis and cirrhosis. Why only some develop progressive disease is not known and maybe dependant on the pathophysiology.

APA, Harvard, Vancouver, ISO, and other styles

5

Fraser, Abigail. "Causes and consequences of nonalcoholic fatty liver disease." Thesis, University of Bristol, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.492651.

Full text

Abstract:

Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of fat in the liver with or without inflammation, fibrosis and cirrhosis, in the absence of substantial alcohol consumption. In this thesis, several potential causes of NAFLD from across the life course, have been investigated, as well as associations of NAFLD with major clinical outcomes. This was done using data from three population based studies: the British Women's Heart and Health Study, a prospective cohort of 4,286 British women ages 60-79; the Caerphilly Prospective Study, a cohort of 2,512 Welsh men ages 40

APA, Harvard, Vancouver, ISO, and other styles

6

Liu, Yang-Lin. "Genomic studies in non-alcoholic fatty liver disease." Thesis, University of Newcastle upon Tyne, 2017. http://hdl.handle.net/10443/3822.

Full text

Abstract:

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum that spans simple steatosis, through steatohepatitis (NASH) to fibrosis and ultimately cirrhosis. NAFLD is characterised by substantial inter-patient variation in rate of progression and disease outcome: whilst up to 25% of the general population are at risk of progressive disease, only a minority experience associated liver-related morbidity. Inter-patient genetic variation and environment determine severity and progression of NAFLD. This thesis reports a series of studies examining the association of genetic variations in two g

APA, Harvard, Vancouver, ISO, and other styles

7

CADDEO, ANDREA MARCO. "The role of MBOAT7 on fatty liver disease." Doctoral thesis, Università degli Studi di Cagliari, 2021. http://hdl.handle.net/11584/345538.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Scorletti, Eleonora. "Effect of omega-3 fatty acids in non-alcoholic fatty liver disease." Thesis, University of Southampton, 2017. https://eprints.soton.ac.uk/422265/.

Full text

Abstract:

The first chapter (Introduction) of the thesis summarises the pathogenesis of NAFLD and its associated risk factors such as type 2 diabetes and cardiovascular disease. Moreover, it describes: a) the potential beneficial effects of long chain omega-3 fatty acid treatment [docosahexaenoic acid (DHA) plus eicosapentaenoic acid (EPA)] in NAFLD; b) the effect of genotypes patatin-like phospholipase domain-containing protein-3 (PNPLA3 I148M) and the transmembrane 6 superfamily member 2 protein (TM6SF2 E167K), on the level of DHA and EPA enrichment and end of study liver fat percentage after DHA+EPA

APA, Harvard, Vancouver, ISO, and other styles

9

Spanos, Christos. "Quantitative liver proteomics for biomarker discovery in non-alcoholic fatty liver disease." Thesis, University of Surrey, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.616323.

Full text

Abstract:

Non-alcoholic fatty liver disease (NAFLD) is now the most common liver disease worldwide. Given that NAFLD can progress from steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and potentially hepatocellular carcinoma, early diagnosis and accurate disease staging are primary clinical concerns. Hypothesizing that a subset of liver proteins will exhibit differential expression in NAFLD and that these proteins may represent candidate disease biomarkers; the aims of this project were to use proteomics to identify differentially expressed proteins both in an in vitro and an in vivo model of

APA, Harvard, Vancouver, ISO, and other styles

10

Al-Serri, Ahmad E. O. F. O. "Genetic factors affecting progression of nonalcoholic fatty liver disease." Thesis, University of Newcastle Upon Tyne, 2011. http://hdl.handle.net/10443/1323.

Full text

Abstract:

Non-alcoholic fatty liver disease (NAFLD) ranges from steatosis to the more progressive form non-alcoholic steatohepatitis. Genetic factors may be important risk determinants for disease progression. This study aimed to assess association of polymorphisms in candidate genes with NAFLD severity and to investigate functional significance of selected polymorphisms Two approaches were used for association studies, case-control analysis on adults (n=351) with biopsy-proven NAFLD and transmission disequilibrium on family trios (n=71) with an index child with NAFLD. A total of 37 polymorphisms in 14

APA, Harvard, Vancouver, ISO, and other styles

11

Hallsworth, Kate. "Physical activity, exercise and non-alcoholic fatty liver disease." Thesis, University of Newcastle upon Tyne, 2012. http://hdl.handle.net/10443/1510.

Full text

Abstract:

Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of liver conditions ranging from hepatic steatosis through steatohepatitis to cirrhosis. Its prevalence has been estimated at between one-in-five and one-in-three of the adult population depending on country and diagnostic criteria used. Prevalence increases with degree of obesity, and is very common in those with Type 2 diabetes (T2DM). Rising prevalence of obesity and T2DM, particularly in younger people, will ensure that NAFLD remains a growing clinical concern for the future. Lifestyle modification, which encompasses diet, wei

APA, Harvard, Vancouver, ISO, and other styles

12

Cheng, Lik-fai, and 鄭力暉. "Non-alcoholic fatty liver disease in Asia: a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2010. http://hub.hku.hk/bib/B45171117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ekstedt, Mattias. "Non-Alcoholic Fatty Liver Disease : A clinical and histopathological study." Doctoral thesis, Linköpings universitet, Gastroenterologi och hepatologi, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-17220.

Full text

Abstract:

Fatty liver has previously often been associated with excessive alcohol consumption. During the last two decades, the interest in fatty liver occurring in non-drinkers i.e. non-alcoholic fatty liver disease (NAFLD) has increased dramatically. Today, NAFLD is considered as the most common liver disease in the developed world. It is strongly associated with obesity, insulin resistance, and hypertension. Thus, NAFLD is considered as the hepatic manifestation of the metabolic syndrome. The spectrum of NAFLD includes: simple fatty liver without necroinflammatory activity; non-alcoholic steatohepati

APA, Harvard, Vancouver, ISO, and other styles

14

Ghadieh, Hilda E. "Impaired Hepatic Insulin Clearance Links Fatty Liver Disease to Atherosclerosis." University of Toledo Health Science Campus / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=mco1533216686796754.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Tan, Elizabeth E.-Lyn. "Immuno-metabolism in Metabolic (dysfunction) associated fatty liver disease (MAFLD)." Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/27978.

Full text

Abstract:

The findings from chronic complex diseases modelled in animals are difficult to extrapolate to humans. In metabolic (dysfunction) associated fatty liver disease (MAFLD), dietary models are commonly used to study the mechanisms for disease progression. The current dogma is that diets rich in fat, simple carbohydrates, and cholesterol can lead to systemic alterations in metabolism that leads to the accumulation of lipids in the adipose and liver tissues. This leads to lipotoxicity and a vicious cycle of inflammation and liver injury which can drive disease progression. Hence, there has been a co

APA, Harvard, Vancouver, ISO, and other styles

16

Ban, Linda. "Role of extracellular vesicles in non-alcoholic fatty liver disease." Thesis, The University of Sydney, 2019. http://hdl.handle.net/2123/20824.

Full text

Abstract:

Once thought to be a benign accumulation of hepatic fat, non-alcoholic fatty liver disease (NAFLD) is now recognised as a prevalent complication of obesity with serious consequences if left untreated. This includes liver inflammation and impaired glucose metabolism, and with time may result in cirrhosis and organ failure. While basic diagnostic tools exist, such as ultrasound and serum protein markers, these are often unreliable and warrant the use of more invasive techniques such as tissue biopsy. Given most patients only become symptomatic once the disease is advanced, there is an urgent nee

APA, Harvard, Vancouver, ISO, and other styles

17

Alshaalan, Rasha. "Non-invasive diagnostic methods for non-alcoholic fatty liver disease." Thesis, McGill University, 2013. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=119567.

Full text

Abstract:

Background: NAFLD is one of the most common causes of liver disease worldwide. It is a spectrum of disease characterized by macrovesicular steatosis of the liver that ranges from simple fatty liver (steatosis), to non-alcoholic steatohepatitis (NASH). NASH may eventually evolve to cirrhosis and end stage complication. Liver biopsy has long been considered the gold standard of reference to diagnose NAFLD but it is costly and invasive. Recently, non-invasive methods have been proposed. Aims and methods: The aim of this study was to investigate the accuracy of non-invasive methods including (Ultr

APA, Harvard, Vancouver, ISO, and other styles

18

Qin, Minhua. "Regulation of genes in patients with non-alcoholic fatty liver disease /." [St. Lucia, Qld.], 2004. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe18501.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Berlanga, Bustos Alba. "Deregulation of fatty acid metabolism and cannabinoid receptors in liver of morbidly obese women with non-alcoholic fatty liver disease." Doctoral thesis, Universitat Rovira i Virgili, 2015. http://hdl.handle.net/10803/325135.

Full text

Abstract:

La malaltia del fetge gras no alcohòlic (MFGNA) inclou un espectre histològic que va des de la esteatosi simple (SS) a l'esteatohepatitis no alcohòlica (EHNA), sent aquesta última freqüentment progressiva. Donat que l'acumulació hepàtica de lípids sembla ser un mecanisme crucial en la patogènesi de la MFGNA, una millor comprensió dels mecanismes subjacents que condueixen a l'acumulació inicial de lipíds hepàtics podria ser de gran interès per controlar la progressió de la malaltia. El sistema endocannabinoide (SE), mitjançant principalment els receptors cannabinoides CB1 i CB2, sembla ser que

APA, Harvard, Vancouver, ISO, and other styles

20

Ghazali, Reem. "Mechanisms into the development of fatty liver disease : role of free fatty acids and alcohol." Thesis, University of Westminster, 2017. https://westminsterresearch.westminster.ac.uk/item/q5vv0/mechanisms-into-the-development-of-fatty-liver-disease-role-of-free-fatty-acids-and-alcohol.

Full text

Abstract:

Background: Alcohol and Free fatty acids such as palmitate are known to promote liver injury. However less mechanistic information is available regarding omega fatty acids ratios with/out alcohol. In healthy populations omega 6/3 ratios are between 1:1 to 4:1, whereas high ratios ( > 15:1) are thought to correlate with the pathogenesis of fatty liver disease. This study aimed to investigate liver lipotoxicity and mitochondrial dysfunction due to imbalanced omega 6/3 ratios alone or in the presence of alcohol. Method: Human hepatoma cell line, VL-17A cells were treated with individual fatty aci

APA, Harvard, Vancouver, ISO, and other styles

21

Mahady, Suzanne E. "Epidemiological studies across the spectrum of elevated liver enzymes and non-alcoholic fatty liver disease." Thesis, The University of Sydney, 2017. http://hdl.handle.net/2123/17180.

Full text

Abstract:

Elevations in the liver enzyme alanine transaminase (ALT), traditionally regarded as a highly specific indicator of liver injury, are now recognised as a novel marker of impaired metabolic health. Elevated ALT has a positive, linear association with the metabolic syndrome and its individual components including truncal adiposity, type 2 diabetes and dyslipidaemia. Prospective data indicates that elevated ALT predicts incident metabolic syndrome and type 2 diabetes in a dose dependent relationship, and may predict incident cardiovascular mortality, although the latter relationship appears non-l

APA, Harvard, Vancouver, ISO, and other styles

22

Krasnoff, Joanne B. "Health-related fitness, physical activity, and non-alcoholic fatty liver disease." [Bloomington, Ind.] : Indiana University, 2007. http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:3274261.

Full text

Abstract:

Thesis (Ph.D.)--Indiana University, School of Health, Physical Education and Recreation, 2007.<br>Source: Dissertation Abstracts International, Volume: 68-07, Section: B, page: 4315. Adviser: Janet P. Wallace. Title from dissertation home page (viewed Apr. 15, 2008).

APA, Harvard, Vancouver, ISO, and other styles

23

Lake, April D. "Hepatic stress response mechanisms in progressive human nonalcoholic fatty liver disease." Thesis, The University of Arizona, 2013. http://pqdtopen.proquest.com/#viewpdf?dispub=3590010.

Full text

Abstract:

<p> Nonalcoholic fatty liver disease (NAFLD) has become a worldwide, chronic liver disease of increasing clinical significance. It is closely associated with the rising epidemics of obesity and insulin resistance. Up to 17% of the United States population may progress from the disease stage characterized as simple, benign steatosis to the more severe, inflammatory stage of nonalcoholic steatohepatitis (NASH). This progression occurs through 2<sup>nd</sup> 'hits' of increased oxidative stress and inflammation to a liver that has been sensitized by lipotoxic stress. NASH is also characterized by

APA, Harvard, Vancouver, ISO, and other styles

24

Cepero, Donates Yuneivy. "Pathogenic role of IL-15 in non-alcoholic fatty liver disease." Mémoire, Université de Sherbrooke, 2014. http://hdl.handle.net/11143/5871.

Full text

Abstract:

Abstract : Pro-inflammatory cytokines play a key role in pathogenesis of obesity and non-alcoholic fatty liver disease (NAFLD). IL-15 is a pro-inflammatory cytokine, which signals through a receptor complex composed of the IL-15 receptor (IL-15R) alpha chain, the IL-2/IL-15R beta chain and the common gamma chain. The functions of IL-15 have been extensively described in immune cells but less is known about its functions in others tissues such as the liver. The aim of this thesis is to investigate the role of IL-15 in fatty liver disease. C57BL/6 wildtype (WT) and IL-15 knockout (Il15[superscr

APA, Harvard, Vancouver, ISO, and other styles

25

Krishnan, Smitha. "Gut Microbiota Metabolites Modulate Inflammation in Non- Alcoholic Fatty Liver Disease." Thesis, Tufts University, 2018. http://pqdtopen.proquest.com/#viewpdf?dispub=10812893.

Full text

Abstract:

<p> Recent findings, including our own work, demonstrated that intestinal microbiota species produce bioactive metabolites that engage host cellular pathways. Microbiota-derived metabolites have also been detected in circulation and in the, setting up the intriguing possibility that these bacterial products could directly interact with host cellular pathways at distant sites. The study described in this abstract investigates the hypothesis that gut microbiota dysbiosis perturbs the balance of immunomodulatory microbiota metabolites, which exacerbates liver inflammation in steatosis. We utilize

APA, Harvard, Vancouver, ISO, and other styles

26

Кириченко, Наталія Миколаївна, Наталия Николаевна Кириченко, Nataliia Mykolaivna Kyrychenko, M. V. Prokopishek, and F. Aldusari. "Hypolipidemic therapy in with metabolic syndrome and nonalcoholic fatty liver disease." Thesis, Сумський державний університет, 2014. http://essuir.sumdu.edu.ua/handle/123456789/35753.

Full text

Abstract:

Metabolic syndrome (MS) and non-alcoholic fatty liver disease (NAFLD) induce significant increase of triglycerides (TG), total cholesterol (TC) and low density lipoproteins (LDL), which is associated with the risk of cardiovascular disease and requires high doses of statins and possibly in combination with fibrates. This combination of drugs can result in a pronounced hepatotoxicity. Therefore, ursodeoxycholic acid (UDCA) was included as a hepatoprotector into the complex treatment of these patients. When you are citing the document, use the following link http://essuir.sumdu.edu.ua/handle/123

APA, Harvard, Vancouver, ISO, and other styles

27

Hamlin, Allyson. "Hepatic Lrp1 deficiency and the development of nonalcoholic fatty liver disease." University of Cincinnati / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1490698940398626.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Alghamdi, Shareefa. "Consequences of non-alcoholic fatty liver disease on drug-induced hepatocytoxicity." Thesis, University of Surrey, 2015. http://epubs.surrey.ac.uk/808210/.

Full text

Abstract:

Non-alcoholic fatty liver disease (NAFLD) is characterised by the accumulation of lipid in liver. Liver is the principal organ involved in drug biotransformation. The central hypothesis of this project is that alterations in the liver environment due to lipid accumulation aggravate sensitivity of hepatocytes to toxicity of some commonly prescribed drugs (paracetamol, alcohol, phenobarbital, cisplatin or doxorubicin). The aim of this study was to investigate the effect of lipid overloading (steatosis) on drug cytotoxicity in the liver model Huh7 cell line. Hepatic steatosis was induced in Huh7

APA, Harvard, Vancouver, ISO, and other styles

29

Alharthi, Jawaher. "A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes." Thesis, The University of Sydney, 2022. https://hdl.handle.net/2123/29842.

Full text

Abstract:

Background: Toll-like receptors (TLRs) are important mediators of inflammatory pathways which play a major role in initiating immune responses. The breakdown of TLR tolerance results in development of liver disease including metabolic (dysfunction) associated fatty liver disease (MAFLD) and COVID-19. Membrane bound O-acyltransferase domain containing 7 (MBOAT7) is a phospholipid modifying enzyme highly expressed in both liver and macrophages. This study reports a novel role of MBOAT7 in MAFLD, through the regulation of TLR receptor signalling. Methods: I have studied the role of MBOAT7 in reg

APA, Harvard, Vancouver, ISO, and other styles

30

Emery, Maurice George. "Aspects of human CYP 2E1 regulation in health and disease /." Thesis, Connect to this title online; UW restricted, 1999. http://hdl.handle.net/1773/7943.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Ashfaq-Khan, Muhammad [Verfasser]. "Dietary wheat amylase trypsin inhibitors worsen chronic liver disease in preclinical models of non-alcoholic fatty liver disease and liver fibrosis / Muhammad Ashfaq-Khan." Mainz : Universitätsbibliothek Mainz, 2018. http://d-nb.info/1173844449/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Wong, Yue-ling, and 黃愉鈴. "The role of adipocyte fatty acid binding protein in the pathogenesis of non-alcoholic fatty liver disease." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2010. http://hub.hku.hk/bib/B45164873.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Pang, Zhenyi. "Non-alcoholic fatty liver disease : real-time PCR analysis of gene expression /." [St. Lucia, Qld.], 2004. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Pugh, Christopher James Alan. "Vascular and metabolic adaption to exercise in non-alcoholic fatty liver disease." Thesis, Liverpool John Moores University, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.570720.

Full text

Abstract:

Non-alcoholic fatty liver disease (NAFLD) is characterised by the accumulation of fat in the liver and is associated with liver-related morbidity and mortality. Nevertheless, the leading cause of death in these patients is cardiovascular disease (CVD). Excess abdominal visceral adipose tissue (VAT) is frequently expressed in NAFLD and is considered a pivotal feature in the pathogenesis ofNAFLD which is predictive of CVD. Endothelial dysfunction is an early manifestation in the development of atherosclerosis and is characterised bya diminished bioavailabilty of the anti-atherogenic molecule NO,

APA, Harvard, Vancouver, ISO, and other styles

35

Boateng, Anthony Osei. "Hepatoprotective properties of Gentiana spp. against non-alcoholic fatty liver disease (NAFLD)." Thesis, University of Westminster, 2018. https://westminsterresearch.westminster.ac.uk/item/q4yzy/hepatoprotective-properties-of-gentiana-spp-against-non-alcoholic-fatty-liver-disease-nafld.

Full text

Abstract:

Non-alcoholic fatty liver disease (NAFLD) is a metabolic disease characterised by the accumulation of fat in the liver. It is estimated that 33 % of the UK population have NAFLD with 2-5 % progressing to non-alcoholic steatohepatitis (NASH). Due to a lack of an outright therapy for NAFLD, treatment has been mainly focussed on managing the conditions associated with the disease such as obesity, diabetes mellitus and hyperlipidaemia. This study aimed to investigate the means by which hepatocyte protection is conferred by Gentiana plants (Gentiana lutea, Gentiana macrophylla, Gentiana scabra and

APA, Harvard, Vancouver, ISO, and other styles

36

Kistler, Kristin David. "Nonalcoholic fatty liver disease quality of life, exercise intensity and histological severity /." Diss., [La Jolla] : [San Diego] : University of California, San Diego ; San Diego State University, 2009. http://wwwlib.umi.com/cr/ucsd/fullcit?p3359523.

Full text

Abstract:

Thesis (Ph. D.)--University of California, San Diego and San Diego State University, 2009.<br>Title from first page of PDF file (viewed July 21, 2009). Available via ProQuest Digital Dissertations. Vita. Includes bibliographical references.

APA, Harvard, Vancouver, ISO, and other styles

37

Chung, Wing Shan Rosanna. "Effects of Dietary Sphingomyelin on Non‐alcoholic Fatty Liver Disease and Atherosclerosis." Thesis, The University of Sydney, 2014. http://hdl.handle.net/2123/13652.

Full text

Abstract:

Sphingomyelin (SM) is ubiquitous in human diets. The studies in this thesis investigated the effects of pure egg SM supplementation on the risks of non-alcoholic fatty liver disease (NAFLD) and atherosclerosis development in various mouse models. High fat-fed C57BL/6 mice, a model for NAFLD, was supplemented with different doses of dietary SM for various duration. The results showed that SM supplementation significantly reduced hepatomegaly, total hepatic lipids, particularly hepatic cholesterol and triglyceride, in a dose-dependent manner after 4 weeks. All of these parameters are risk facto

APA, Harvard, Vancouver, ISO, and other styles

38

Purwaha, Preeti. "Effect of Dietary Omega-3 and Omega-6 Polyunsaturated Fatty Acids on Alcoholic Liver Disease." Diss., North Dakota State University, 2012. https://hdl.handle.net/10365/26488.

Full text

Abstract:

PUFAs have been shown to modulate ALD by several mechanisms, including free radical generation from hepatic lipid peroxidation. However, how they modulate lipid peroxidation and generation of bioactive metabolites in ALD is poorly understood and it is still not clear which PUFAs (?-3 or ?-6) are beneficial or detrimental in ALD. Thus, our objective was to study the effect of ?-3/?-6 PUFAs on lipid peroxidation and ethanol mediated steatosis and inflammation. Using standard liquid diet (LDC), LDC with fish oil (rich in ?-3) and safflower oil (rich in ?-6), we studied the generation of bioactive

APA, Harvard, Vancouver, ISO, and other styles

39

MacFarlane, David Peter. "Factors determining the progression of nonalcoholic fatty liver disease : the role of abnormal fatty acid and glucocorticoid metabolism." Thesis, University of Edinburgh, 2011. http://hdl.handle.net/1842/5914.

Full text

Abstract:

Obesity and insulin resistance are associated with a constellation of features including hypertension, dyslipidaemia, type 2 diabetes, and premature cardiovascular disease, collectively termed the metabolic syndrome. Non-alcoholic fatty liver disease (NAFLD) represents the hepatic component of this syndrome, incorporating a spectrum of liver disease with increasing morbidity and mortality, from simple steatosis, to non-alcoholic steatohepatitis (or NASH), fibrosis, cirrhosis and ultimately hepatocellular carcinoma. However, factors influencing this progression are incompletely understood. In t

APA, Harvard, Vancouver, ISO, and other styles

40

Käräjämäki, A. (Aki). "Non-alcoholic fatty liver disease (NAFLD):perspectives to etiology, complications and lipid metabolism." Doctoral thesis, Oulun yliopisto, 2017. http://urn.fi/urn:isbn:9789526217376.

Full text

Abstract:

Abstract Obesity, insulin resistance, type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD) form a dangerous quartet which threatens human health all over the world. About 25% of adults around the world have NAFLD, which poses risks for cardiovascular and metabolic well-being and may develop into liver cirrhosis and hepatocellular carcinoma. Apart from lifestyle modification, treatment options for NAFLD are scarce. This thesis presents atrial fibrillation (AF) as a new complication of NAFLD among general population of 958 individuals aged 40-60 years participating in the OPERA st

APA, Harvard, Vancouver, ISO, and other styles

41

Penke, Melanie. "The NAD salvage pathway during the progression of non-alcoholic fatty liver disease." Doctoral thesis, Universitätsbibliothek Leipzig, 2016. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-194821.

Full text

Abstract:

Non-alcoholic fatty liver disease (NAFLD) is a major chronic liver disease and thus a main reason for liver-related morbidities and mortality. NAFLD covers a wide range of diseases starting with steatosis and frequently progressing to non-alcoholic steatohepatitis (NASH), which is an independent predictor for the development of the hepatocellular carcinoma (HCC). Nicotinamide phosphoribosyltransferase (NAMPT), the key enzyme of the mammalian NAD salvage pathway, recycles nicotinamide to nicotinamide mononucleotide (NMN), which is further converted to nicotinamide adenine dinucleotide (NAD). NA

APA, Harvard, Vancouver, ISO, and other styles

42

Lyall, Marcus James. "TET mediated 5’hydroxymethylation in the pathogenesis of non alcoholic fatty liver disease." Thesis, University of Edinburgh, 2017. http://hdl.handle.net/1842/29524.

Full text

Abstract:

Non-alcoholic fatty liver disease (NAFLD) now affects around one in four adults in the human population and parallels the global increase in obesity. Within the spectrum of NAFLD, simple steatosis is associated with insulin resistance and type 2 diabetes while progression to steatohepatitis (NASH) is associated with an increased risk of liver cirrhosis and all-cause mortality. The molecular pathology of NAFLD is incompletely understood, however observational studies in human cohorts suggest the regulation of DNA methylation may play a role. 5-hydroxymethylcytosine (5hmC) is a cytosine modifica

APA, Harvard, Vancouver, ISO, and other styles

43

Li, Xilin. "Role of Diet and Xenobiotics in the Progression of Nonalcoholic Fatty Liver Disease." Thesis, Indiana University, 2018. http://pqdtopen.proquest.com/#viewpdf?dispub=10830274.

Full text

Abstract:

<p> Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease. The spectrum of NAFLD ranges from simple steatosis, to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and potentially hepatocellular carcinoma. Dietary factors and chemical exposure have been associated with the disease progression. In addition, the presence of NAFLD changes the metabolism of drugs and chemicals, which may in turn increase the susceptibility of the liver to xenobiotic induced toxicity. To examine the potential interplay of chemicals on diet-induced NAFLD, three stud

APA, Harvard, Vancouver, ISO, and other styles

44

Мелеховець, Оксана Костянтинівна, Оксана Константиновна Мелеховец, Oksana Kostiantynivna Melekhovets, and D. O. Lukyanenko. "Features of dyslipidemia in patients with hypothyroidism combined with nonalcoholic fatty liver disease." Thesis, Sumy State University, 2016. http://essuir.sumdu.edu.ua/handle/123456789/47926.

Full text

Abstract:

Background. The problem of nonalcoholic fatty liver disease (NAFLD) is very important nowadays. On the one hand, the characteristic of it is wide spread and on the other hand – there are a lot of factual material about the pathogenic mechanisms of development. Decompensated hypothyroidism leads to dyslipidemia in any age. The aim of this study is the definition of the peculiarities of dyslipidemia for patients with the combination of hypothyroidism and NAFLD.

APA, Harvard, Vancouver, ISO, and other styles

45

Fisher, Craig. "Non-Alcoholic Fatty Liver Disease Alters the Three Stages of Hepatic Drug Management." Diss., The University of Arizona, 2008. http://hdl.handle.net/10150/195795.

Full text

Abstract:

In pharmacotherapeutics, the term "correct dosing" is based on the concept that too high a systemic concentration will lead to drug toxicity, while drug levels that are too low may not produce the intended therapeutic effect. Often, the factors determining the ability of a patient to manage a given dose rely on their capacity to efficiently metabolize and eliminate drugs from the body. The liver plays a crucial role in the processing of many clinically relevant drugs via three stages of hepatic drug management. Drugs must first be taken into hepatocytes by uptake transporters. Drugs are th

APA, Harvard, Vancouver, ISO, and other styles

46

Lin, Hui-Ting, and 林惠婷. "The Extracts of Mulberry Leaves inhibits Non-Alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/52558303651182285354.

Full text

Abstract:

碩士<br>中山醫學大學<br>生化暨生物科技研究所<br>102<br>Non-alcoholic fatty liver disease (NAFLD), a leading cause of liver damage, comprises of a spectrum of liver abnormalities including the early fat deposition in the liver (hepatic steatosis) and advanced nonalcoholic steatohepatitis (NASH). In addition, alcoholic liver disease (ALD) also lead to similar liver syndrome with NASH.In previous studies, mulberry leaves had been demonstrated to possess anti-oxidantant promoting effects. In this study, we have examined the effect of water extracts of mulberry leaves (MLE) on HFD-induced hepatic steatosis in rats.

APA, Harvard, Vancouver, ISO, and other styles

47

"Nonalcoholic fatty liver disease in Hong Kong Chinese." Thesis, 2009. http://library.cuhk.edu.hk/record=b6074763.

Full text

Abstract:

Among NAFLD patients without known diabetes or high fasting plasma glucose at or above 7.0 mmol/I, 21% had undiagnosed diabetes and 29% had impaired glucose tolerance. In this population, post-challenge hyperglycemia was associated with NASH and liver fibrosis. Oral glucose tolerance test should be considered in the evaluation of NAFLD patients.<br>NAFLD is closely related to metabolic syndrome. Using the ethnic-specific IDF criteria, 70% of NAFLD patients had metabolic syndrome, compared to 7% of the general population. A significant proportion of NAFLD patients had body mass index between 23

APA, Harvard, Vancouver, ISO, and other styles

48

HSU, REN-YI, and 許任儀. "Study of Arctigenin Against Nonalcoholic Fatty Liver Disease." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/94080179599518681368.

Full text

Abstract:

碩士<br>中華科技大學<br>健康科技研究所<br>104<br>After the control of hepatitis viruses and westernization of the lifestyle in Taiwan, an increasing burden of Nonalcoholic fatty liver disease (NAFLD) is anticipated and active prophylactic measures should be implemented. NAFLD is a clinicopathological term that encompasses a spectrum of abnormalities ranging from simple triglyceride accumulation in the hepatocytes to hepatic steatosis with inflammation, also known as nonalcoholic steatohepatitis (NASH). NASH can also progress to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. In this study, lipid d

APA, Harvard, Vancouver, ISO, and other styles

49

Tai, Chi-Ming, and 戴啟明. "Nonalcoholic Fatty Liver Disease in Severely Obese Patients." Thesis, 2015. http://ndltd.ncl.edu.tw/handle/28181231610480042740.

Full text

Abstract:

博士<br>高雄醫學大學<br>臨床醫學研究所博士班<br>104<br>Background: With the increasing prevalence of obesity, nonalcoholic steatohepatitis (NASH) will become an important issue of public health and morbidly obese patients are especially the high-risk group of NASH. Simple steatosis is thought to be a benign status but about 10 to 29% of individuals with NASH develop cirrhosis within 10 years. Liver biopsy is still the gold standard for the differential diagnosis between simple steatosis and NASH, however, it is an invasive procedure which limit the research of NASH in morbidly obese patients. More and more morb

APA, Harvard, Vancouver, ISO, and other styles

50

Rui-XiangGuo and 郭瑞祥. "A Predictive Model for Nonalcoholic Fatty Liver Disease." Thesis, 2011. http://ndltd.ncl.edu.tw/handle/87563006031481162388.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!